What Makes Repare Therapeutics (RPTX) a New Buy Stock

Core Viewpoint - Repare Therapeutics Inc. (RPTX) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook driven by an upward trend in earnings estimates, which significantly influences stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The correlation between earnings estimate revisions and near-term stock price movements is strong, making the Zacks rating system valuable for investors [3][7]. - For the fiscal year ending December 2025, Repare Therapeutics is expected to earn -$2.24 per share, reflecting a -13.7% change from the previous year [9]. - Over the past three months, the Zacks Consensus Estimate for Repare Therapeutics has increased by 28.3%, indicating a positive trend in earnings estimates [9]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The upgrade of Repare Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].